Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
November 13, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
October 28, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
October 23, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024 08:45 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
April 05, 2023 07:00 ET
|
Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
Proxygen Announces Formation of Board of Directors
March 15, 2023 07:00 ET
|
Proxygen
VIENNA, Austria, March 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s board of...